Content
All Posts > Content under Healthcare
Biotech Digest – GMED Receives Clearance, BIOC Inks New Collaboration, PFE Receives Approval
Article By:
KKD Healthcare Analytics
Read
Friday, August 18, 2017 2:03 PM EDT
Globus Medical Inc. stock perked up as the company announced receiving the 510 (k) clearance from the FDA for Excelsius GPS. AstraZeneca announced receiving the FDA approval for its Lynparzaa. Pfizer has FDA approval for its Besponsa.
Health Insurance Innovations - Chart Of The Day
Article By:
Jim Van Meerten
Read
Thursday, August 17, 2017 2:00 PM EDT
The Chart of the Day belongs to Health Insurance Innovations. Since the Trend Spotter signaled a buy on 5/4 the stock gained 71.07%.
In this article: HIIQ
Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection
Article By:
The Life Sciences Report
Read
Thursday, August 17, 2017 1:17 PM EDT
Inovio Pharmaceuticals Inc. exited Q2/17 with $92 million in cash. It has closed a public offering that yielded $70.5 million, which "would be used for general corporate purposes, including clinical trial expenses.
In this article: INO
The Cannabis Distribution Quagmire In Nevada Has Caused A Sharp Decline In Sales
Article By:
Technical420
Read
Thursday, August 17, 2017 1:09 PM EDT
Shortly after Nevada's recreational marijuana program launched in July, a state of emergency was reported when dispensaries did not have enough product to support demand.
In this article: VPGDF
Can Pfizer Bank On New Immunotherapy Bavencio For Growth?
Article By:
Zacks Investment Research
Read
Thursday, August 17, 2017 12:59 PM EDT
As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc.’s newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant.
Why Diligence Matters: Don’t Buy Acadia Healthcare’s Roll-Up
Article By:
David Trainer
Read
Wednesday, August 16, 2017 12:48 PM EDT
Acadia operates in the Behavioral Healthcare field, which focuses on treating people with mental illness and addiction. The industry is fairly fragmented, and the bull case for Acadia has rested on the idea that it can reap gains.
In this article: ACHC
Kindred Healthcare Not A Good Bet For Individual Investor
Article By:
Kate Hayden
Read
Wednesday, August 16, 2017 11:58 AM EDT
Less than 5% of KND is held by individual investors, and the recent changes to its core mission underline why this is one best left to the professionals.
In this article: KND
How Much Higher Can The 'Dow' Go?
Article By:
Jennifer Coombs
Read
Wednesday, August 16, 2017 3:36 AM EDT
When the Dow Jones Industrial Average hit 20,000 for the first time earlier this year, no one could really imagine that several months later we would witness the index reach 2,000 points more.
Stocks To Watch: HFC, TRN, AMGN
Article By:
Ryan Mallory
Read
Wednesday, August 16, 2017 12:11 AM EDT
Today's stock picks include HollyFrontier, Trinity Industries and Amgen.
Investors Expecting Growth From Large Caps And M&A From Mid-Caps
Article By:
Rod Raynovich
Read
Tuesday, August 15, 2017 9:37 PM EDT
Biotech stocks in general have recovered from last week’s sell-off and remain in a monthly trend up despite a topping pattern from July. Despite weak seasonality and lack of M&A the sector is holding lows with good volume.
Teva Stock Is Getting Destroyed. Is Now The Time To Buy?
Article By:
Modest Money
Read
Tuesday, August 15, 2017 5:29 PM EDT
Is there any reason for a value investor to invest in Teva? At this point, I can’t think of one. The reason being is that there is nothing on the immediate horizon that will cause the stock price to jump.
In this article: TEVA
20 Questions For NuLife Sciences CEO John B. Hollister
Article By:
Terry Chrisomalis
Read
Tuesday, August 15, 2017 12:26 PM EDT
An inside look at a small company looking to have a big impact in transplant technology.
In this article: NULF
Your Retirement Can’t Wait For The Next Crash
Article By:
The Dividend Guy
Read
Tuesday, August 15, 2017 1:14 AM EDT
I don’t know about you, but I have the feeling the market is beating new highs every week or so this year. This leads me toward many articles explaining how the market is way too high right now and the next crash will be happening anytime soon.